← Eichor
Study identifier: NCT05197764 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Macroscopic Muscle Growth in Infants and Young Children With Spastic Cerebral Palsy

Condition: Spastic Cerebral Palsy · Acquired Brain Injury  ·  Sponsor: Universitaire Ziekenhuizen KU Leuven

PhaseN/A
Planned participants229
Who can joinAll sexes, 6 Months to 9 Years
Healthy volunteersYes

About this study

A mixed longitudinal design study will be carried out to explore the onset and time course of morphological muscle changes on a macroscopic level in children with spastic cerebral palsy (SCP). Therefore, this project aims to (1) describe the macroscopic morphological muscle changes with increasing age and (2) evaluate the onset and development of muscle alterations in relation to the brain lesion (e.g., timing, extent and location), to the neuromuscular impairments and to treatment. Overall, this project will evaluate the macroscopic muscle properties by means of 3D freehand ultrasound (3DfUS).

This description comes directly from the study's public registry record.

Talk to the study team

Nathalie De Beukelaer  ·  +3216341016  ·  Nathalie.debeukelaer@kuleuven.be

Lauraine Staut  ·  lauraine.staut@kuleuven.be

Always discuss trial participation with your own doctor first.

Locations (1)

UZ LeuvenLeuven, Vlaams-Brabant, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05197764